Skip to main content
Fig. 3 | Cost Effectiveness and Resource Allocation

Fig. 3

From: Cost-effectiveness of pemigatinib as a second-line treatment for advanced intrahepatic cholangiocarcinoma with fibroblast growth factor receptor 2 fusions in Taiwan: from the evidence of the phase II trial and the perspective of Taiwan's National Health Insurance Administration

Fig. 3

Scenario analysis results: Base-case analysis and probabilistic sensitivity analysis of all scenarios in this study. Costs listed in 2022 NT dollars. mFOLFOX a combination of oxaliplatin, folinic acid, and fluorouracil, 5-FU fluorouracil, ICER incremental cost-effectiveness ratio, INMB incremental net monetary benefit, EVPI expected value of perfect information, CI confidence interval, AE adverse event

Back to article page

Cost Effectiveness and Resource Allocation

ISSN: 1478-7547

Contact us